Recent Research Analysts’ Ratings Updates for Moderna (MRNA)

Several brokerages have updated their recommendations and price targets on shares of Moderna (NASDAQ: MRNA) in the last few weeks:

• 2/23/2026 – Moderna had its price target raised by Piper Sandler from $63.00 to $69.00. They now have an “overweight” rating on the stock.
• 2/17/2026 – Moderna had its price target raised by Royal Bank Of Canada from $25.00 to $30.00. They now have a “sector perform” rating on the stock.
• 2/17/2026 – Moderna was given a new $35.00 price target by Evercore Inc.
• 2/17/2026 – Moderna had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $45.00 price target on the stock.
• 2/17/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a “neutral” rating on the stock.
• 2/16/2026 – Moderna had its “neutral” rating reaffirmed by UBS Group AG. They now have a $36.00 price target on the stock.
• 2/16/2026 – Moderna had its “neutral” rating reaffirmed by Citigroup Inc..
• 2/16/2026 – Moderna was given a new $30.00 price target by Morgan Stanley.
• 1/30/2026 – Moderna had its “underperform” rating reaffirmed by Leerink Partners.
• 1/29/2026 – Moderna had its “hold” rating reaffirmed by TD Cowen.
• 1/28/2026 – Moderna is now covered by Barclays PLC. They set an “equal weight” rating and a $25.00 price target on the stock.
• 1/19/2026 – Moderna had its “neutral” rating reaffirmed by Citigroup Inc..
• 1/17/2026 – Moderna was upgraded by Wall Street Zen from “sell” to “hold”.
• 1/12/2026 – Moderna was upgraded by BMO Capital Markets from “market perform” to “buy”.
• 1/12/2026 – Moderna had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
• 1/6/2026 – Moderna was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $34.00 price target on the stock, down from $40.00.
• 1/5/2026 – Moderna had its “hold” rating reaffirmed by Jefferies Financial Group Inc..

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 23,853 shares of Moderna stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the transaction, the director directly owned 3,924 shares in the company, valued at $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Stephen Hoge sold 160,009 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the transaction, the president directly owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. The trade was a 9.89% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 184,366 shares of company stock worth $8,531,936. Corporate insiders own 10.90% of the company’s stock.

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.